Tenon Medical, Inc. Stock Price, News & Analysis

Tenon Medical (NASDAQ:TNON) reported Q3 2025 revenue of $1.2M, a 32% year-over-year increase driven by record Catamaran procedure volumes and the addition of SImmetry product sales. Gross profit was $773K with a 66% gross margin, up from 47% a year earlier. Q3 net loss was $3.3M (‑$0.40 per share). Cash and cash equivalents were $3.4M at September 30, 2025, and subsequent to quarter end the company raised $2.85M in PIPE financing. Tenon completed the SiVantage acquisition, expanded commercial training (26 physicians trained), and launched Catamaran SE and SImmetry+ activity to broaden its multi-product SI fusion portfolio.

Tenon Medical (NASDAQ:TNON) announced an at-the-market PIPE financing priced on November 11, 2025 to raise gross proceeds of $2,850,000. Under securities purchase agreements dated September 10, 2025, the company will issue 2,217,904 shares of common stock and warrants to purchase 2,217,904 shares at a combined offering price of $1.285 per share plus warrant. The PIPE warrants carry a $1.16 strike price and expire three years from issuance. The Issued Shares and warrant shares will have customary resale registration rights. Closing is subject to customary conditions. Tenon intends to use proceeds for working capital, product launches, commercial expansion, clinical studies, and core operations.

Tenon Medical (NASDAQ:TNON) will release third quarter 2025 financial results for the period ended September 30, 2025 after market close on Thursday, November 13, 2025. The company will host a conference call the same day at 4:30 p.m. Eastern Time to discuss results and hold a Q&A with covering analysts.

Dial-in details: US 1-877-407-0792, Int'l 1-201-689-8263. Webcast available via the TNON conference call link. Audio playback will be available through November 27, 2025 on Tenon’s investor relations site or by telephone replay (1-844-512-2921 US; 1-412-317-6671 Int'l) using access code 13756541.

Tenon Medical (NASDAQ:TNON) announced FDA 510(k) clearance for the SImmetry+ SI Joint Fusion System on October 21, 2025. The minimally invasive lateral-access system uses new 3D-printed titanium implants, joint decortication, bone graft delivery, and fixation to enable SI joint fusion. Tenon plans an alpha launch targeting year-end 2025 with select physician users to gather initial feedback ahead of broader commercial rollout. SImmetry+ joins Tenon's Catamaran platform, expanding multi-approach SI fusion options supported by published prospective studies.

Tenon Medical (NASDAQ:TNON) announced compelling 12-month results from its MAINSAIL™ study evaluating the Catamaran® SI Joint Fusion System. The study showed significant clinical improvements, with pain scores (VAS) decreasing from 78.8mm to 23.0mm and disability scores (ODI) improving from 51.6% to 20.8%. 83% of patients demonstrated unequivocal fusion evidence at 12 months.

The study, involving 24 patients across six U.S. clinical sites, reported no serious adverse events and high patient satisfaction, with 83.3% reporting satisfaction at 12 months. The surgical efficiency was notable, with 45.7% of procedures completed in under 45 minutes. These results exceed average improvements reported in previous literature for SI joint fusion procedures.

Tenon Medical (NASDAQ:TNON) has announced the full commercial launch of its Catamaran® SE SI Joint Fusion System, expanding its implant portfolio for sacroiliac joint fusion procedures. The new system features a smaller implant profile compared to the original Catamaran Fixation Device, designed for patients with smaller SI joint anatomy or revision surgeries.

The system includes a dedicated instrument set with a manual drilling option and leverages enhanced commercial capabilities from the recent SiVantage acquisition. The titanium implant has demonstrated strong clinical performance with over 1,000 devices implanted to date, showing promising early results in the MAINSAIL Clinical Study for achieving successful fusion.

Tenon Medical (NASDAQ:TNON) reported Q2 2025 financial results, highlighting its strategic acquisition of SiVantage portfolio. The company posted revenue of $0.6 million, down from $0.9 million in Q2 2024, with a net loss of $2.8 million compared to $3.8 million in the prior year.

Key highlights include operating expenses reduction of 29% year-over-year, FDA clearance for Catamaran® as an adjunct to thoracolumbar fixation, and successful completion of initial case series. The company maintained a strong financial position with $7.8 million in cash and no outstanding debt as of June 30, 2025.

The SiVantage acquisition is expected to accelerate topline growth through immediate revenue generation, expanded market access, and strengthened hospital pathways, with integration planned over the next 60-90 days.

Tenon Medical (NASDAQ:TNON), a company focused on Sacroiliac Joint (SIJ) disorders treatment, will release its Q2 2025 financial results after market close on Wednesday, August 13, 2025.

The company will host a conference call at 4:30 p.m. Eastern Time on the same day, featuring a Q&A session with covering analysts. The call will be accessible via telephone and webcast, with replay available through August 27, 2025 on Tenon's Investor Relations website.

Tenon Medical (NASDAQ:TNON) has acquired sacroiliac joint-specific assets from SiVantage, including their SImmetry® and SImmetry+™ technologies. The strategic acquisition transforms Tenon into a multi-product, multi-approach sacro-pelvic organization, expanding its portfolio across multiple approaches to sacro-pelvic anatomy.

The transaction brings critical technologies, intellectual property, and key leadership to Tenon, with SiVantage's co-founders joining as Chief Innovations Officer and Chief Commercial Officer. The deal structure includes an upfront cash component and equity issuance, with most consideration tied to future performance milestones. Integration is expected to complete in Q4 2025.

The acquisition immediately strengthens Tenon's product pipeline and is expected to contribute to revenue, supported by extensive clinical data demonstrating safety and performance in sacroiliac joint fusion procedures.